BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37926331)

  • 1. Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation.
    Thor M; Fitzgerald K; Apte A; Oh JH; Iyer A; Odiase O; Nadeem S; Yorke ED; Chaft J; Wu AJ; Offin M; Simone Ii CB; Preeshagul I; Gelblum DY; Gomez D; Deasy JO; Rimner A
    Radiother Oncol; 2024 Jan; 190():109983. PubMed ID: 37926331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PET/CT radiomics model for predicting distant metastasis in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy: a multicentric study.
    Yu L; Zhang Z; Yi H; Wang J; Li J; Wang X; Bai H; Ge H; Zheng X; Ni J; Qi H; Guan Y; Xu W; Zhu Z; Xing L; Dekker A; Wee L; Traverso A; Ye Z; Yuan Z
    Radiat Oncol; 2024 Jan; 19(1):10. PubMed ID: 38254106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicentric development and evaluation of [
    Lucia F; Louis T; Cousin F; Bourbonne V; Visvikis D; Mievis C; Jansen N; Duysinx B; Le Pennec R; Nebbache M; Rehn M; Hamya M; Geier M; Salaun PY; Schick U; Hatt M; Coucke P; Hustinx R; Lovinfosse P
    Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1097-1108. PubMed ID: 37987783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment
    Dissaux G; Visvikis D; Da-Ano R; Pradier O; Chajon E; Barillot I; Duvergé L; Masson I; Abgral R; Santiago Ribeiro MJ; Devillers A; Pallardy A; Fleury V; Mahé MA; De Crevoisier R; Hatt M; Schick U
    J Nucl Med; 2020 Jun; 61(6):814-820. PubMed ID: 31732678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiblock Discriminant Analysis of Integrative
    Lee SH; Kao GD; Feigenberg SJ; Dorsey JF; Frick MA; Jean-Baptiste S; Uche CZ; Cengel KA; Levin WP; Berman AT; Aggarwal C; Fan Y; Xiao Y
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1451-1465. PubMed ID: 33662459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognositc significance of SUV
    Dong M; Liu J; Sun X; Xing L
    J Med Imaging Radiat Oncol; 2017 Oct; 61(5):652-659. PubMed ID: 28266166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
    Tan D; Gill S; Loh N
    Cancer Med; 2020 Oct; 9(20):7469-7476. PubMed ID: 32846054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.
    Ebright MI; Russo GA; Gupta A; Subramaniam RM; Fernando HC; Kachnic LA
    J Thorac Cardiovasc Surg; 2013 Mar; 145(3):709-15. PubMed ID: 23317944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cone-beam CT radiomics features might improve the prediction of lung toxicity after SBRT in stage I NSCLC patients.
    Qin Q; Shi A; Zhang R; Wen Q; Niu T; Chen J; Qiu Q; Wan Y; Sun X; Xing L
    Thorac Cancer; 2020 Apr; 11(4):964-972. PubMed ID: 32061061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response assessment of stereotactic body radiation therapy using dynamic contrast-enhanced integrated MR-PET in non-small cell lung cancer patients.
    Huang YS; Chen JL; Hsu FM; Huang JY; Ko WC; Chen YC; Jaw FS; Yen RF; Chang YC
    J Magn Reson Imaging; 2018 Jan; 47(1):191-199. PubMed ID: 28480541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
    Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
    J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Han J; Song Q; Guo F; Du R; Fang H; Kang J; Lu Z
    Nucl Med Commun; 2022 Jun; 43(6):717-724. PubMed ID: 35354781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
    Nair VJ; MacRae R; Sirisegaram A; Pantarotto JR
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):312-8. PubMed ID: 24411602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of Risk Survival Measures Estimated From Pre- and Posttreatment Computed Tomography Scans Improves Stratification of Patients With Early-Stage Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy.
    Jiao Z; Li H; Xiao Y; Aggarwal C; Galperin-Aizenberg M; Pryma D; Simone CB; Feigenberg SJ; Kao GD; Fan Y
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1647-1656. PubMed ID: 33333202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A radiomic approach to predicting nodal relapse and disease-specific survival in patients treated with stereotactic body radiation therapy for early-stage non-small cell lung cancer.
    Franceschini D; Cozzi L; De Rose F; Navarria P; Fogliata A; Franzese C; Pezzulla D; Tomatis S; Reggiori G; Scorsetti M
    Strahlenther Onkol; 2020 Oct; 196(10):922-931. PubMed ID: 31722061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A SUV
    Ye L; Xu F; Shi S; Zeng Z; Jin X; Huang Y; Lu C; Gu J; Ge D; He J
    Clin Transl Oncol; 2018 Aug; 20(8):1026-1034. PubMed ID: 29327241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
    Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
    Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.